|
1
|
McDonnell DP, Park S, Goulet MT, Jasper J,
Wardell SE, Chang CY, Norris JD, Guyton JR and Nelson ER: Obesity,
cholesterol metabolism, and breast cancer pathogenesis. Cancer Res.
74:4976–4982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stebbing J, Sharma A, North B, Athersuch
TJ, Zebrowski A, Pchejetski D, Coombes RC, Nicholson JK and Keun
HC: A metabolic phenotyping approach to understanding relationships
between metabolic syndrome and breast tumour responses to
chemotherapy. Ann Oncol. 23:860–866. 2012. View Article : Google Scholar
|
|
3
|
Hirayama A, Kami K, Sugimoto M, Sugawara
M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, et
al: Quantitative metabolome profiling of colon and stomach cancer
microenvironment by capillary electrophoresis time-of-flight mass
spectrometry. Cancer Res. 69:4918–4925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiu F, Chen YR, Liu X, Chu CY, Shen LJ, Xu
J, Gaur S, Forman HJ, Zhang H, Zheng S, et al: Arginine starvation
impairs mitochondrial respiratory function in ASS1-deficient breast
cancer cells. Sci Signal. 7:ra312014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Possemato R, Marks KM, Shaul YD, Pacold
ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, et
al: Functional genomics reveal that the serine synthesis pathway is
essential in breast cancer. Nature. 476:346–350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amelio I, Cutruzzolá F, Antonov A,
Agostini M and Melino G: Serine and glycine metabolism in cancer.
Trends Biochem Sci. 39:191–198. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu G and Morris SM Jr: Arginine
metabolism: Nitric oxide and beyond. Biochem J. 336:1–17. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vissers YL, Dejong CH, Luiking YC, Fearon
KC, von Meyenfeldt MF and Deutz NE: Plasma arginine concentrations
are reduced in cancer patients: Evidence for arginine deficiency?
Am J Clin Nutr. 81:1142–1146. 2005.PubMed/NCBI
|
|
9
|
Daly JM, Reynolds J, Thom A, Kinsley L,
Dietrick-Gallagher M, Shou J and Ruggieri B: Immune and metabolic
effects of arginine in the surgical patient. Ann Surg. 208:512–523.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Talamonti MS, Kim SP, Yao KA, Wayne JD,
Feinglass J, Bennett CL and Rao S: Surgical outcomes of patients
with gastric carcinoma: The importance of primary tumor location
and microvessel invasion. Surgery. 134:720–729. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yerushalmi HF, Besselsen DG, Ignatenko NA,
Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Guillen JM,
Holubec H, Payne CM and Gerner EW: Role of polyamines in
arginine-dependent colon carcinogenesis in
ApcMin/+ mice. Mol Carcinog. 45:764–773.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park KG, Heys SD, Blessing K, Kelly P,
McNurlan MA, Eremin O and Garlick PJ: Stimulation of human breast
cancers by dietary L-arginine. Clin Sci. 82:413–417. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yeatman TJ, Risley GL and Brunson ME:
Depletion of dietary arginine inhibits growth of metastatic tumor.
Arch Surg. 126:1376–1382. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma Q, Wang Y, Gao X, Ma Z and Song Z:
L-arginine reduces cell proliferation and ornithine decarboxylase
activity in patients with colorectal adenoma and adenocarcinoma.
Clin Cancer Res. 13:7407–7412. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr
M, Spector S and Savaraj N: Arginine deprivation as a targeted
therapy for cancer. Curr Pharm Des. 14:1049–1057. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Phillips MM, Sheaff MT and Szlosarek PW:
Targeting arginine-dependent cancers with arginine-degrading
enzymes: Opportunities and challenges. Cancer Res Treat.
45:251–262. 2013. View Article : Google Scholar
|
|
17
|
Delage B, Fennell DA, Nicholson L, McNeish
I, Lemoine NR, Crook T and Szlosarek PW: Arginine deprivation and
arginino-succinate synthetase expression in the treatment of
cancer. Int J Cancer. 126:2762–2772. 2010.PubMed/NCBI
|
|
18
|
Shen LJ and Shen WC: Drug evaluation:
ADI-PEG-20 - a PEGylated arginine deiminase for
arginine-auxotrophic cancers. Curr Opin Mol Ther. 8:240–248.
2006.PubMed/NCBI
|
|
19
|
Shen LJ, Beloussow K and Shen WC:
Modulation of arginine metabolic pathways as the potential
anti-tumor mechanism of recombinant arginine deiminase. Cancer
Lett. 231:30–35. 2006. View Article : Google Scholar
|
|
20
|
Dillon BJ, Prieto VG, Curley SA, Ensor CM,
Holtsberg FW, Bomalaski JS and Clark MA: Incidence and distribution
of argininosuccinate synthetase deficiency in human cancers: A
method for identifying cancers sensitive to arginine deprivation.
Cancer. 100:826–833. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ensor CM, Holtsberg FW, Bomalaski JS and
Clark MA: Pegylated arginine deiminase (ADI-SS PEG20,000
mw) inhibits human melanomas and hepatocellular carcinomas in
vitro and in vivo. Cancer Res. 62:5443–5450. 2002.PubMed/NCBI
|
|
22
|
Bowles TL, Kim R, Galante J, Parsons CM,
Virudachalam S, Kung HJ and Bold RJ: Pancreatic cancer cell lines
deficient in argininosuccinate synthetase are sensitive to arginine
deprivation by arginine deiminase. Int J Cancer. 123:1950–1955.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH,
Kim JH, Park IS, Yoon DK and Min BH: Renal cell carcinoma does not
express argininosuccinate synthetase and is highly sensitive to
arginine deprivation via arginine deiminase. Int J Cancer.
120:897–905. 2007. View Article : Google Scholar
|
|
24
|
Feun LG, Marini A, Walker G, Elgart G,
Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, et al:
Negative argininosuccinate synthetase expression in melanoma
tumours may predict clinical benefit from arginine-depleting
therapy with pegylated arginine deiminase. Br J Cancer.
106:1481–1485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Erez A, Nagamani SC, Shchelochkov OA,
Premkumar MH, Campeau PM, Chen Y, Garg HK, Li L, Mian A, Bertin TK,
et al: Requirement of argininosuccinate lyase for systemic nitric
oxide production. Nat Med. 17:1619–1626. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Turner MA, Simpson A, McInnes RR and
Howell PL: Human argininosuccinate lyase: A structural basis for
intragenic complementation. Proc Natl Acad Sci USA. 94:9063–9068.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang HL, Hsu HP, Shieh SC, Chang YS, Chen
WC, Cho CY, Teng CF, Su IJ, Hung WC and Lai MD: Attenuation of
argininosuccinate lyase inhibits cancer growth via cyclin A2 and
nitric oxide. Mol Cancer Ther. 12:2505–2516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cunard R and Sharma K: The endoplasmic
reticulum stress response and diabetic kidney disease. Am J Physiol
Renal Physiol. 300:F1054–F1061. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee AH, Scapa EF, Cohen DE and Glimcher
LH: Regulation of hepatic lipogenesis by the transcription factor
XBP1. Science. 320:1492–1496. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Eno CO, Altman BJ, Zhu Y, Zhao G,
Olberding KE, Rathmell JC and Li C: ER stress modulates cellular
metabolism. Biochem J. 435:285–296. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Clarke HJ, Chambers JE, Liniker E and
Marciniak SJ: Endoplasmic reticulum stress in malignancy. Cancer
Cell. 25:563–573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang G, Yang ZQ and Zhang K: Endoplasmic
reticulum stress response in cancer: Molecular mechanism and
therapeutic potential. Am J Transl Res. 2:65–74. 2010.PubMed/NCBI
|
|
33
|
Malhi H and Kaufman RJ: Endoplasmic
reticulum stress in liver disease. J Hepatol. 54:795–809. 2011.
View Article : Google Scholar
|
|
34
|
Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi
NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH and Hotamisligil
GS: Endoplasmic reticulum stress links obesity, insulin action, and
type 2 diabetes. Science. 306:457–461. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Barbosa-Tessmann IP, Chen C, Zhong C,
Schuster SM, Nick HS and Kilberg MS: Activation of the unfolded
protein response pathway induces human asparagine synthetase gene
expression. J Biol Chem. 274:31139–31144. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Okada T, Yoshida H, Akazawa R, Negishi M
and Mori K: Distinct roles of activating transcription factor 6
(ATF6) and double-stranded RNA-activated protein kinase-like
endoplasmic reticulum kinase (PERK) in transcription during the
mammalian unfolded protein response. Biochem J. 366:585–594. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liang XH, Jackson S, Seaman M, Brown K,
Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and
inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oyadomari S, Gotoh T, Aoyagi K, Araki E,
Shichiri M and Mori M: Coinduction of endothelial nitric oxide
synthase and arginine recycling enzymes in aorta of diabetic rats.
Nitric Oxide. 5:252–260. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Korde Choudhari S, Sridharan G, Gadbail A
and Poornima V: Nitric oxide and oral cancer: A review. Oral Oncol.
48:475–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lechner M, Lirk P and Rieder J: Inducible
nitric oxide synthase (iNOS) in tumor biology: The two sides of the
same coin. Semin Cancer Biol. 15:277–289. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al: The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature. 486:346–352.
2012.PubMed/NCBI
|
